pharmaphorum
@pharmaphorum.bsky.social
pharmaphorum.com, and its magazine Deep Dive, is a leading online destination for pharmaceutical industry and healthcare news, insight, and debate
February 6, 2026 at 4:56 PM
Three years after its first launch in the US, there are signs that #Biogen and #Eisai's #Alzheimer's #Leqembi therapy is gathering sales momentum.
pharmaphorum.com/news/leqembi...
pharmaphorum.com/news/leqembi...
February 6, 2026 at 4:19 PM
Three years after its first launch in the US, there are signs that #Biogen and #Eisai's #Alzheimer's #Leqembi therapy is gathering sales momentum.
pharmaphorum.com/news/leqembi...
pharmaphorum.com/news/leqembi...
#Bayer's oral Factor XIa inhibitor asundexian can reduce the risk of a secondary ischaemic #stroke by 26%, according to the OCEANIC-STROKE trial.
pharmaphorum.com/news/bayer-r...
pharmaphorum.com/news/bayer-r...
February 6, 2026 at 1:58 PM
#Bayer's oral Factor XIa inhibitor asundexian can reduce the risk of a secondary ischaemic #stroke by 26%, according to the OCEANIC-STROKE trial.
pharmaphorum.com/news/bayer-r...
pharmaphorum.com/news/bayer-r...
#GenerateBiomedicines has filed for an #IPO on the #Nasdaq, seeking to raise upwards of $100m for phase 3 trials of its twice-yearly #asthma drug. #lifesciences #biotechnews #respiratoryhealth pharmaphorum.com/news/flagshi...
February 5, 2026 at 2:29 PM
#GenerateBiomedicines has filed for an #IPO on the #Nasdaq, seeking to raise upwards of $100m for phase 3 trials of its twice-yearly #asthma drug. #lifesciences #biotechnews #respiratoryhealth pharmaphorum.com/news/flagshi...
#Amgen confirmed on its fourth-quarter results call that it has resisted a request to pull Tavneos for ANCA-associated #vasculitis from the US market. #ANCAAssociatedVasculitis
#RareDisease #pharmanews #lifesciences pharmaphorum.com/news/amgen-b...
#RareDisease #pharmanews #lifesciences pharmaphorum.com/news/amgen-b...
February 5, 2026 at 2:24 PM
#Amgen confirmed on its fourth-quarter results call that it has resisted a request to pull Tavneos for ANCA-associated #vasculitis from the US market. #ANCAAssociatedVasculitis
#RareDisease #pharmanews #lifesciences pharmaphorum.com/news/amgen-b...
#RareDisease #pharmanews #lifesciences pharmaphorum.com/news/amgen-b...
In today’s news: pharmaphorum.com/news #pharmanews
February 4, 2026 at 4:56 PM
In today’s news: pharmaphorum.com/news #pharmanews
In today's headlines: pharmaphorum.com/news
February 3, 2026 at 5:06 PM
In today's headlines: pharmaphorum.com/news
#SummitTherapeutics has moved ahead in the race to bring a therapy targeting both #VEGF and #PDL1 to market, after the #FDA started a review of its ivonescimab drug for #lungcancer.
buff.ly/PtZy4pn
buff.ly/PtZy4pn
January 30, 2026 at 3:00 PM
#SummitTherapeutics has moved ahead in the race to bring a therapy targeting both #VEGF and #PDL1 to market, after the #FDA started a review of its ivonescimab drug for #lungcancer.
buff.ly/PtZy4pn
buff.ly/PtZy4pn
#AstraZeneca is already deeply embedded in #China's pharma sector, and is hungry for more, pledging $15 billion to an #investment programme in the country and signing a mammoth #licensing deal with Hong Kong-listed #CSPCPharma.
pharmaphorum.com/news/az-deep...
pharmaphorum.com/news/az-deep...
January 30, 2026 at 10:55 AM
#AstraZeneca is already deeply embedded in #China's pharma sector, and is hungry for more, pledging $15 billion to an #investment programme in the country and signing a mammoth #licensing deal with Hong Kong-listed #CSPCPharma.
pharmaphorum.com/news/az-deep...
pharmaphorum.com/news/az-deep...
#EikonTherapeutics, former MSD head of R&D #RogerPerlmutter's new project, is hoping to raise up to $318 million from a #Nasdaq listing, in another signal of building confidence in the #biopharma sector.
pharmaphorum.com/news/eikon-p...
pharmaphorum.com/news/eikon-p...
January 28, 2026 at 6:58 PM
#EikonTherapeutics, former MSD head of R&D #RogerPerlmutter's new project, is hoping to raise up to $318 million from a #Nasdaq listing, in another signal of building confidence in the #biopharma sector.
pharmaphorum.com/news/eikon-p...
pharmaphorum.com/news/eikon-p...
#BoehringerIngelheim has added another drug to its #immunology pipeline, #licensing an inflammatory bowel disease (#IBD) candidate from China's #Simcere in a deal that would be worth up to €1.05 billion ($1.25 billion).
buff.ly/IgGNk6v
buff.ly/IgGNk6v
January 27, 2026 at 4:30 PM
#BoehringerIngelheim has added another drug to its #immunology pipeline, #licensing an inflammatory bowel disease (#IBD) candidate from China's #Simcere in a deal that would be worth up to €1.05 billion ($1.25 billion).
buff.ly/IgGNk6v
buff.ly/IgGNk6v
#Roche has reported phase 2 results with a dual GIP/#GLP1 agonist #obesity candidate, achieving #weightloss of up to 22.5%, as it prepares for a phase 3 programme.
buff.ly/syPVtFl
buff.ly/syPVtFl
January 27, 2026 at 3:00 PM
#Roche has reported phase 2 results with a dual GIP/#GLP1 agonist #obesity candidate, achieving #weightloss of up to 22.5%, as it prepares for a phase 3 programme.
buff.ly/syPVtFl
buff.ly/syPVtFl
In this second of three articles on The #SundayTimes top 100 #techcompanies list, pharmaphorum is focusing on the first nine of 18 #startups featuring in the #hardware category. #lifesciences
pharmaphorum.com/news/introdu...
pharmaphorum.com/news/introdu...
January 27, 2026 at 11:41 AM
In this second of three articles on The #SundayTimes top 100 #techcompanies list, pharmaphorum is focusing on the first nine of 18 #startups featuring in the #hardware category. #lifesciences
pharmaphorum.com/news/introdu...
pharmaphorum.com/news/introdu...
Thousands of men with advanced #prostatecancer will be offered a new treatment, #Pfizer's #Talzenna, from today after #NICE made an about-turn on the drug.
pharmaphorum.com/news/change-...
pharmaphorum.com/news/change-...
January 23, 2026 at 11:33 AM
Thousands of men with advanced #prostatecancer will be offered a new treatment, #Pfizer's #Talzenna, from today after #NICE made an about-turn on the drug.
pharmaphorum.com/news/change-...
pharmaphorum.com/news/change-...
US healthcare giant #JohnsonandJohnson has said that after a "catapult year" in 2025, it is on course to report around $100 billion in #sales this year for the first time.
pharmaphorum.com/news/jj-says...
pharmaphorum.com/news/jj-says...
January 22, 2026 at 2:22 PM
US healthcare giant #JohnsonandJohnson has said that after a "catapult year" in 2025, it is on course to report around $100 billion in #sales this year for the first time.
pharmaphorum.com/news/jj-says...
pharmaphorum.com/news/jj-says...
#Roche's #Gazyvaro, a drug that can restore #kidneyfunction in people living with #lupusnephritis, has been cleared for use by the #NHS in England and Wales.
pharmaphorum.com/news/nice-ba...
pharmaphorum.com/news/nice-ba...
January 22, 2026 at 12:00 PM
#Roche's #Gazyvaro, a drug that can restore #kidneyfunction in people living with #lupusnephritis, has been cleared for use by the #NHS in England and Wales.
pharmaphorum.com/news/nice-ba...
pharmaphorum.com/news/nice-ba...
The #EuropeanCommission has approved #Otsuka's #Dawnzera for the prevention of recurrent attacks in #raredisease hereditary angioedema (#HAE), a drug that can be self-administered by patients with weeks between doses.
pharmaphorum.com/news/eu-appr...
pharmaphorum.com/news/eu-appr...
January 21, 2026 at 3:27 PM
The #EuropeanCommission has approved #Otsuka's #Dawnzera for the prevention of recurrent attacks in #raredisease hereditary angioedema (#HAE), a drug that can be self-administered by patients with weeks between doses.
pharmaphorum.com/news/eu-appr...
pharmaphorum.com/news/eu-appr...
Shares in #ImmunityBio rose sharply after the company said it has agreed a path with the #FDA that will allow it to refile for approval of wider use of its #bladdercancer therapy, #Anktiva, in papillary-only disease.
pharmaphorum.com/news/immunit...
pharmaphorum.com/news/immunit...
January 21, 2026 at 12:45 PM
Shares in #ImmunityBio rose sharply after the company said it has agreed a path with the #FDA that will allow it to refile for approval of wider use of its #bladdercancer therapy, #Anktiva, in papillary-only disease.
pharmaphorum.com/news/immunit...
pharmaphorum.com/news/immunit...
Long-term follow-up data from a phase 2b trial of #Moderna and #MSD's #mRNA-based #vaccine against #melanoma, intismeran autogene (mRNA-4157), show an impressive 49% reduction in the risk of disease progression or death.
pharmaphorum.com/news/data-bu...
pharmaphorum.com/news/data-bu...
January 21, 2026 at 10:39 AM
Long-term follow-up data from a phase 2b trial of #Moderna and #MSD's #mRNA-based #vaccine against #melanoma, intismeran autogene (mRNA-4157), show an impressive 49% reduction in the risk of disease progression or death.
pharmaphorum.com/news/data-bu...
pharmaphorum.com/news/data-bu...
#NovoNordisk's new chief executive, #MikeDoustdar, has told the #JPM2026 Healthcare conference that the key to competing in the #GLP1 agonist category for #weightloss will be to make the most of cash-pay channels.
pharmaphorum.com/news/jpm-nov...
pharmaphorum.com/news/jpm-nov...
January 14, 2026 at 3:51 PM
#NovoNordisk's new chief executive, #MikeDoustdar, has told the #JPM2026 Healthcare conference that the key to competing in the #GLP1 agonist category for #weightloss will be to make the most of cash-pay channels.
pharmaphorum.com/news/jpm-nov...
pharmaphorum.com/news/jpm-nov...
The #FDA has asked manufacturers of #GLP1 agonist medicines used for #weightloss to remove #warnings that they may cause suicidal thoughts.
pharmaphorum.com/news/fda-see...
pharmaphorum.com/news/fda-see...
January 14, 2026 at 2:30 PM
The #FDA has asked manufacturers of #GLP1 agonist medicines used for #weightloss to remove #warnings that they may cause suicidal thoughts.
pharmaphorum.com/news/fda-see...
pharmaphorum.com/news/fda-see...
New data from the #UK medicines #regulator has shown an increase in #clinicaltrial activity in the country, after years of decline, which it says shows that the promise of reforms is already starting to have an effect.
pharmaphorum.com/news/jpm-uks...
pharmaphorum.com/news/jpm-uks...
January 13, 2026 at 10:39 AM
New data from the #UK medicines #regulator has shown an increase in #clinicaltrial activity in the country, after years of decline, which it says shows that the promise of reforms is already starting to have an effect.
pharmaphorum.com/news/jpm-uks...
pharmaphorum.com/news/jpm-uks...
#JiangsuHengruiPharma has chalked up a first-in-class approval for retlirafusp alfa, a #bifunctionaldrug that targets #PDL1 and #TGFbeta, as a treatment for advanced #gastriccancer.
pharmaphorum.com/news/hengrui...
pharmaphorum.com/news/hengrui...
January 8, 2026 at 12:52 PM
#JiangsuHengruiPharma has chalked up a first-in-class approval for retlirafusp alfa, a #bifunctionaldrug that targets #PDL1 and #TGFbeta, as a treatment for advanced #gastriccancer.
pharmaphorum.com/news/hengrui...
pharmaphorum.com/news/hengrui...
Eight digital health technologies (#DHTs) designed to support people with #asthma can be used by the #NHS in England while additional evidence of their benefits is gathered.
pharmaphorum.com/news/nice-en...
pharmaphorum.com/news/nice-en...
January 7, 2026 at 12:39 PM
Eight digital health technologies (#DHTs) designed to support people with #asthma can be used by the #NHS in England while additional evidence of their benefits is gathered.
pharmaphorum.com/news/nice-en...
pharmaphorum.com/news/nice-en...
#GSK's antisense-based drug for chronic #hepatitisB (CHB), bepirovirsen, has hit the mark in two phase 3 trials and will be filed for approval as a potential first-in-class treatment for the disease.
pharmaphorum.com/news/gsk-pre...
pharmaphorum.com/news/gsk-pre...
January 7, 2026 at 10:53 AM
#GSK's antisense-based drug for chronic #hepatitisB (CHB), bepirovirsen, has hit the mark in two phase 3 trials and will be filed for approval as a potential first-in-class treatment for the disease.
pharmaphorum.com/news/gsk-pre...
pharmaphorum.com/news/gsk-pre...